When Antidepressants Have Not Worked: How Spravato Differs from Traditional Depression Treatments at Innovative MindCare in Chicago and Downers Grove

For many adults living with depression, the journey toward relief can be long and discouraging. Standard antidepressant medications help a significant number of people, but they do not work for everyone. When two or more antidepressants have failed to provide adequate improvement, the condition is often classified as treatment-resistant depression (TRD) – and it can leave patients feeling as though they have exhausted their options. Spravato treatment in Chicago offers a clinically distinct alternative for individuals in this situation. At Innovative MindCare, patients in Chicago and Downers Grove can access this FDA-approved nasal spray therapy as part of a medically supervised treatment plan designed specifically for those who have not responded to traditional approaches.

Understanding Treatment-Resistant Depression

Treatment-resistant depression is not a rare occurrence. Research estimates suggest that approximately one-third of adults with major depressive disorder (MDD) do not achieve adequate symptom relief after trying multiple conventional antidepressants. For these individuals, each unsuccessful trial can deepen feelings of hopelessness and fatigue with the treatment process itself.

TRD is generally defined as a failure to respond meaningfully to at least two different antidepressant medications, each taken at an appropriate dose and for an adequate duration. It is important to understand that this classification does not reflect a personal failing. Rather, it reflects the complex neurobiology of depression, which varies significantly from person to person. Some brains simply do not respond to the mechanisms that traditional antidepressants rely on – which is precisely why newer treatment modalities like Spravato (esketamine nasal spray) have been developed.

How Traditional Antidepressants Work – and Why They Sometimes Fall Short

To appreciate what makes Spravato different, it helps to understand how conventional antidepressant medications function. The most commonly prescribed classes of antidepressants include:

• Selective serotonin reuptake inhibitors (SSRIs) – such as sertraline, fluoxetine, and escitalopram
• Serotonin-norepinephrine reuptake inhibitors (SNRIs) – such as venlafaxine and duloxetine
• Tricyclic antidepressants (TCAs) – such as amitriptyline and nortriptyline
• Monoamine oxidase inhibitors (MAOIs) – such as phenelzine and tranylcypromine

These medications primarily target monoamine neurotransmitters – serotonin, norepinephrine, and dopamine. They work by increasing the availability of these chemical messengers in the brain, which may help regulate mood over time. However, there are several well-documented limitations:

Delayed Onset of Action

Traditional antidepressants typically require four to eight weeks of consistent use before patients may notice meaningful improvement. For someone in acute distress, this waiting period can feel unbearable, particularly if the medication ultimately proves ineffective and the process must begin again with a different drug.

Limited Mechanism of Action

Because most standard antidepressants operate along the same monoamine pathways, switching from one to another may not address the underlying neurological factors driving a patient’s depression. If the root issue lies outside the serotonin or norepinephrine systems, these medications may continue to fall short regardless of how many are tried.

Side Effects That Limit Adherence

Common side effects of traditional antidepressants – including weight gain, sexual dysfunction, fatigue, and gastrointestinal disturbances – can reduce patient adherence, making it difficult to complete a full trial and accurately assess whether a medication is working.

What Is Spravato and How Does It Work Differently?

Spravato (esketamine nasal spray) was approved by the FDA for two specific indications: treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder who have suicidal thoughts or actions. It represents a fundamentally different pharmacological approach compared to traditional antidepressants.

A Different Neurotransmitter System

Rather than targeting serotonin or norepinephrine, Spravato acts on the glutamate system – the brain’s most abundant excitatory neurotransmitter. Specifically, esketamine is an NMDA receptor antagonist. By modulating glutamate activity, Spravato is believed to promote the restoration of synaptic connections in brain areas affected by depression. This mechanism is distinct from anything offered by SSRIs, SNRIs, TCAs, or MAOIs, which is why it may help patients who have not responded to those medication classes.

Faster Potential Onset

One of the most notable differences patients and clinicians observe is the speed at which Spravato may begin to take effect. While traditional antidepressants can take weeks to show results, many patients receiving Spravato have reported noticing changes in their depressive symptoms within hours to days after their initial sessions. This faster potential onset is particularly relevant for individuals experiencing severe depressive episodes or those with suicidal ideation, where time is a critical factor.

Administered Under Medical Supervision

Unlike oral antidepressants that patients take at home, Spravato must be administered in a certified healthcare setting under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. This means every treatment session takes place with direct clinical oversight. At Innovative MindCare, patients receiving Spravato treatment in Chicago or at the Downers Grove location are monitored by trained medical professionals throughout their session, which typically involves a two-hour observation period following administration.

Comparing Spravato and Traditional Antidepressants: Key Differences at a Glance

The following comparison highlights the primary distinctions between Spravato and conventional antidepressant medications across several clinically relevant categories:

• Mechanism of action: Traditional antidepressants target monoamine neurotransmitters (serotonin, norepinephrine, dopamine). Spravato targets the glutamate system via NMDA receptor modulation.
• FDA indication: Traditional antidepressants are approved for MDD broadly. Spravato is approved specifically for treatment-resistant depression and MDD with suicidal thoughts or actions in adults.
• Route of administration: Traditional antidepressants are taken orally at home. Spravato is a nasal spray administered in a certified clinical setting.
• Onset of effect: Traditional antidepressants may take four to eight weeks. Spravato may produce noticeable changes within hours to days in some patients.
• Supervision requirement: Traditional antidepressants do not require in-office administration. Spravato requires medical supervision and a post-administration observation period at every session.
• Treatment schedule: Traditional antidepressants are taken daily. Spravato is typically administered twice weekly during the induction phase, transitioning to weekly or biweekly sessions during maintenance.
• Use alongside other medications: Spravato is prescribed in conjunction with an oral antidepressant, not as a standalone replacement.

It is worth emphasizing that Spravato is not designed to replace traditional antidepressants entirely. It is used in combination with an oral antidepressant and is specifically intended for patients who have not achieved adequate results from prior medication trials. This complementary approach is a key distinction that sets it apart from simply switching between conventional drugs.

What to Expect During Spravato Treatment at Innovative MindCare

For patients considering Spravato treatment in Chicago or the surrounding suburbs, understanding the treatment process can help set realistic expectations. At Innovative MindCare, the experience is structured to prioritize safety, comfort, and clinical effectiveness.

Initial Evaluation

Before beginning treatment, patients undergo a thorough clinical evaluation to confirm that Spravato is an appropriate option. This includes a review of medical history, current medications, and prior antidepressant trials. The goal is to ensure that the patient meets the clinical criteria for treatment-resistant depression or MDD with suicidal thoughts or actions.

Treatment Sessions

During each session, the patient self-administers the nasal spray under the guidance of clinical staff. The process itself is brief, but patients are required to remain at the clinic for approximately two hours afterward for monitoring. During this observation period, the care team checks vital signs and assesses for any side effects, which may include temporary dizziness, dissociation, nausea, or sedation. These effects are generally short-lived and resolve before the patient leaves.

Treatment Schedule

The typical Spravato protocol involves an induction phase of twice-weekly sessions for the first four weeks, followed by a maintenance phase with sessions occurring weekly or every two weeks. The specific schedule is determined by the treating clinician based on each patient’s response and clinical needs.

Ongoing Monitoring

Because Spravato is part of the REMS program, every session includes medical supervision. Innovative MindCare’s team in both Chicago and Downers Grove ensures that patients receive consistent follow-up and adjustments to their treatment plan as needed.

Insurance Coverage for Spravato at Innovative MindCare

One of the practical advantages of Spravato compared to some other advanced depression treatments is that it is typically covered by major insurance providers. Innovative MindCare accepts Aetna, Cigna, Blue Cross Blue Shield, UnitedHealthcare, Medicare, and Medicaid for Spravato treatment. This broader insurance acceptance may make Spravato a more accessible option for patients who need advanced care but are concerned about out-of-pocket costs. Patients are encouraged to contact the clinic directly to discuss their specific coverage.

Is Spravato Right for You?

Spravato is not a universal solution for all forms of depression, and it is not intended as a first-line treatment. It is specifically designed for adults whose depression has not responded adequately to conventional antidepressant therapy. For those patients, however, it represents a meaningfully different treatment approach – one that works through a distinct neurological pathway, may produce faster results, and is delivered within a structured, medically supervised environment.

As with any medical treatment, individual results vary. Some patients experience significant improvement in depressive symptoms, while others may see more modest benefits. The decision to pursue Spravato should be made in close consultation with a qualified healthcare provider who can evaluate your full clinical picture and help determine whether this treatment aligns with your needs.

If you or a loved one has been struggling with depression that has not responded to traditional antidepressants, Innovative MindCare provides spravato treatment in Chicago and Downers Grove within a supportive, clinically rigorous setting. To learn more about whether Spravato may be appropriate for your situation, contact Innovative MindCare to schedule a consultation with their clinical team.